Our preliminary results are in keeping with findings from previous experimental work in fetal lambs.”
“The present study was performed to optimize the formulation of metoprolol succinate (MS) sustained release tablets using hydroxypropyl methylcellulose (HPMC) and sodium alginate (SA) as the matrix combination. After investigating the effects of various parameters on drug release, a 2-factor, 5-level central composite design was employed, using the amount of HPMC K4M (A) and SA (318 cP) (B) as the independent variables and the drug percentage released at 1h, 4h, 8h, 20h (Q(1), Q(4), Q(8), Q(20)) as the responses. Response surfaces were established to obtain the matrix ranges and the
main factors affecting four responses. In order to validate the optimization Roscovitine mw study, six confirmatory runs were performed; indicating high predictability of response
surface methodology for MS sustained release tablets. Data fitting to Peppas equation indicated that the mechanism of drug release could be diffusion along with erosion. This matrix combination can be used as a good alternative to the commercially pellet technology, which was complicated, time-consuming and energy-intensive.”
“Objective: The study aimed to review the results of endovascular aneurysm repair (EVAR) using a novel sac-anchoring endoprosthesis in patients with favourable and adverse anatomy.
Design: This is a prospective, multicentre, clinical trial.
Materials: The Nellix endoprosthesis consists
of dual, balloon-expandable endoframes, surrounded by polymer-filled endobags, which obliterate the aneurysm this website sac and maintain endograft position.
Methods: The study reviewed worldwide clinical experience and Core Lab evaluation of computed tomography (CT) scans.
Results: From 2008 to 2010, 34 patients (age 71 +/- 8 years, abdominal aortic aneurysm (MA) diameter 5.8 +/- 0.8 cm) were treated at four clinical sites. Seventeen patients (50%) met the inclusion criteria for Food and Drug Administration (FDA)-approved endografts (favourable anatomy); 17 (50%) had one or BEZ235 molecular weight more adverse anatomic feature: neck length <10 mm (24%), neck angle >60 degrees (9%) and iliac diameter >23 mm (38%). Device deployment was successful in all patients; iliac aneurysm treatment preserved hypogastric patency. Perioperative mortality was 1/34 (2.9%); one patient died at 10 months of congestive heart failure (CHF); one patient had a secondary procedure at 15 months. During 15 +/- 6 months follow-up, there were no differences in outcome between favourable and adverse anatomy patients. Follow-up CT extending up to 2 years revealed no change in aneurysm size or endograft position and no new endoleaks.
Conclusions: Favourable and adverse anatomy patients can be successfully treated using the Nellix sac-anchoring endoprosthesis. Early results are promising but longer-term studies are needed.